A new administration often brings significant changes to the regulatory environment and the Biden Administration will not be the exception. Areas to watch include antitrust, privacy and CFIUS issues arising in mergers and acquisitions involving technology and the biotech industries.
Please join us for a wide-ranging discussion that in which our panel of subject experts will discuss how the Biden administration is likely to impact the antitrust and privacy landscape in M&A transactions, including federal privacy, data breach and antitrust legislation and the intersection of privacy and antitrust. They will also discuss how CFIUS changed under the Trump administration and what aspects are likely to change—and remain the same—under a Biden administration.
Juliana Campbell
jcampbell@wsgr.comRob represents technology and life sciences clients in M&A and other transformative deals.
Jamillia represents clients in several areas, including merger review, government investigations, and antitrust-related counseling and litigation.
Stephen advises clients on laws and policies at the intersection of international business and national security. He previously served in the U.S. government on the Committee on Foreign Investment in the U.S.